Nanoparticles interact with biological fluids and plasma proteins at nano-bio interface affect their biopharmaceutical properties and biodistribution due to protein corona composition. The PrC composition of various designed LFs was evaluated ex vivo in human plasma by label-free quantitative proteomics.